Christopher P.  Lowe net worth and biography

Christopher Lowe Biography and Net Worth

CFO of Cortexyme
Christopher Lowe has served as our Chief Operating Officer since February 2021, Chief Financial Officer since January 2019 and as our Treasurer since April 2019. From June 2018 until January 2019, Mr. Lowe served as a consultant to us and our interim Chief Financial Officer through his capacity as a partner at FLG Partners. Mr. Lowe has also served as the Managing Partner of the Innventus Fund at Innventure since January 2017 and he has served as a partner at FLG Partners since January 2014 and its Managing Partner since January 2018. Prior to joining Cortexyme, Mr. Lowe served as the Interim Chief Executive Officer and Chief Financial Officer of Hansen Medical from February 2014 to July 2016, and he served as the Chief Business Officer and Chief Financial Officer of Anthera Pharmaceuticals from September 2007 to June 2013. Mr. Lowe served as a director for Inspyr Therapeutics from September 2016 to December 2018. He also served as a director of EpiBiome from May 2016 to June 2018, and he served as a director and Chairman of the Audit Committee for Asante Solutions from December 2014 to October 2015. Mr. Lowe holds a B.S. in Business Administration from California Polytechnic State University and an M.B.A. from St. Mary’s University.

What is Christopher P. Lowe's net worth?

The estimated net worth of Christopher P. Lowe is at least $59,072.00 as of August 24th, 2022. Mr. Lowe owns 28,400 shares of Cortexyme stock worth more than $59,072 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Lowe may own. Learn More about Christopher P. Lowe's net worth.

How do I contact Christopher P. Lowe?

The corporate mailing address for Mr. Lowe and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Christopher P. Lowe's contact information.

Has Christopher P. Lowe been buying or selling shares of Cortexyme?

Christopher P. Lowe has not been actively trading shares of Cortexyme during the last ninety days. Most recently, Christopher P. Lowe sold 4,963 shares of the business's stock in a transaction on Tuesday, October 5th. The shares were sold at an average price of $98.50, for a transaction totalling $488,855.50. Learn More on Christopher P. Lowe's trading history.

Who are Cortexyme's active insiders?

Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

Christopher P. Lowe Insider Trading History at Cortexyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/5/2021Sell4,963$98.50$488,855.50View SEC Filing Icon  
8/16/2021Sell22,000$95.31$2,096,820.00View SEC Filing Icon  
See Full Table

Christopher P. Lowe Buying and Selling Activity at Cortexyme

This chart shows Christopher P Lowe's buying and selling at Cortexyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cortexyme Company Overview

Cortexyme logo
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.08
Low: $1.80
High: $2.14

50 Day Range

MA: $1.07
Low: $0.69
High: $1.95

2 Week Range

Now: $2.08
Low: $1.78
High: $40.66

Volume

312,412 shs

Average Volume

620,672 shs

Market Capitalization

$62.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4